UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 41 filers reported holding UNIQURE NV in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6,939,202 | +2.5% | 605,515 | +80.2% | 0.02% | -11.8% |
Q1 2023 | $6,768,369 | -49.1% | 336,066 | -52.9% | 0.02% | -60.5% |
Q2 2022 | $13,295,000 | +200.9% | 713,240 | +191.7% | 0.04% | +207.1% |
Q1 2022 | $4,418,000 | +888.4% | 244,487 | +1034.8% | 0.01% | +600.0% |
Q4 2021 | $447,000 | -88.4% | 21,545 | -79.4% | 0.00% | -92.9% |
Q3 2020 | $3,849,000 | +415.3% | 104,500 | +563.7% | 0.03% | +211.1% |
Q1 2020 | $747,000 | -91.7% | 15,745 | -87.5% | 0.01% | -83.3% |
Q4 2019 | $9,046,000 | +933.8% | 126,236 | +467.6% | 0.05% | +800.0% |
Q3 2019 | $875,000 | -90.4% | 22,242 | -80.1% | 0.01% | -89.7% |
Q2 2019 | $9,080,000 | +1772.2% | 111,795 | +1276.3% | 0.06% | +1833.3% |
Q1 2019 | $485,000 | -91.6% | 8,123 | -94.9% | 0.00% | -88.5% |
Q3 2018 | $5,767,000 | +41.3% | 158,471 | +46.7% | 0.03% | +36.8% |
Q2 2018 | $4,082,000 | +15.9% | 108,000 | -37.3% | 0.02% | -26.9% |
Q3 2015 | $3,523,000 | +588.1% | 172,292 | +719.0% | 0.03% | +550.0% |
Q1 2015 | $512,000 | – | 21,038 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |